Notably, R-2-hydroxyglutarate (R-2HG) competitively binds to the Fe2+ site in the active center of FTO, thereby regulating m6A modification of mRNAs such as MYC and PFKP, and inhibiting the proliferation and aerobic glycolysis of AML and GBM cells [69, 149]. The gene discussed is MYC; the disease is glioblastoma.